BMEA · Insider Trading
Biomea Fusion, Inc. Common Stock
Every open-market purchase and sale reported by BMEA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Elizabeth Faust | Director | A | +196,299 deriv. | — |
| 2026-06-12 | Julianne Averill | Director | A | +173,711 deriv. | — |
| 2026-06-12 | Sumita Ray | Director | A | +196,299 deriv. | — |
| 2026-06-12 | Eric Aguiar | Director | A | +196,299 deriv. | — |
| 2026-04-03 | Rainer M Erdtmann | See Remarks | A | +452,512 deriv. | — |
| 2026-04-03 | Michael J.M. Hitchcock | Interim CEO | A | +667,477 deriv. | — |
| 2025-12-15 | Rainer M Erdtmann | See Remarks | Buy | +30,000 | +$43.00K |
| 2025-12-04 | Michael J.M. Hitchcock | Interim CEO | Buy | +100,000 | +$99.18K |
| 2025-12-02 | Rainer M Erdtmann | See Remarks | Buy | +50,000 | +$54.55K |
| 2025-08-13 | Michael J.M. Hitchcock | Interim CEO | A | +916,434 deriv. | — |
| 2025-08-13 | Rainer M Erdtmann | See Remarks | G | −40,000 | — |
| 2025-08-01 | Cormorant Global Healthcare Master Fund, LP | — | — | — | — |
| 2025-07-24 | Julianne Averill | Director | A | +241,177 deriv. | — |
| 2025-06-13 | Elizabeth Faust | Director | A | +91,970 deriv. | — |
| 2025-06-13 | Sumita Ray | Director | A | +91,970 deriv. | — |
| 2025-06-13 | Eric Aguiar | Director | A | +91,970 deriv. | — |
| 2025-06-13 | Cormorant Private Healthcare Fund III LP | 10%+ Owner | A | — | — |
| 2025-03-28 | Michael J.M. Hitchcock | Interim CEO | A | +350,000 deriv. | — |
| 2024-12-02 | Franco Valle | Chief Financial Officer | A | +495 | +$3.05K |
| 2024-10-01 | Michael J.M. Hitchcock | Director | Buy | +10,000 | +$100.60K |
| 2024-06-13 | Eric Aguiar | Director | A | +51,025 deriv. | — |
| 2024-06-13 | Michael J.M. Hitchcock | Director | A | +51,025 deriv. | — |
| 2024-06-13 | Sumita Ray | Director | A | +51,025 deriv. | — |
| 2024-06-13 | Elizabeth Faust | Director | A | +51,025 deriv. | — |
| 2024-06-13 | Cormorant Global Healthcare Master Fund, LP | 10%+ Owner | A | — | — |
| 2024-06-12 | Juan Pablo Frias | Chief Medical Officer | A | +349 | +$3.12K |
| 2024-06-12 | Franco Valle | Chief Financial Officer | MIXED | +16,957 | +$72.19K |
| 2024-01-18 | Juan Pablo Frias | Chief Medical Officer | A | +111,090 deriv. | — |
| 2024-01-18 | Thomas Andrew Butler | Chief Executive Officer | A | +407,502 deriv. | — |
| 2024-01-18 | Franco Valle | Chief Financial Officer | A | +145,245 deriv. | — |
| 2024-01-18 | Rainer M Erdtmann | President and COO | A | +135,700 deriv. | — |
| 2024-01-03 | Rainer M Erdtmann | President and COO | G | −12,000 | — |
| 2023-12-01 | Franco Valle | Chief Financial Officer | A | +1,345 | +$5.09K |
| 2023-09-01 | Juan Pablo Frias | Chief Medical Officer | A | +300,000 deriv. | — |
| 2023-06-16 | Eric Aguiar | Director | A | +6,989 deriv. | — |
| 2023-06-16 | Elizabeth Faust | Director | A | +6,989 deriv. | — |
| 2023-06-16 | Sumita Ray | Director | A | +6,989 deriv. | — |
| 2023-06-16 | Michael J.M. Hitchcock | Director | A | +6,989 deriv. | — |
| 2023-06-16 | Bihua Chen | Director | A | — | — |
| 2023-06-02 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | −125,000 | −$4.26M |
| 2023-06-02 | Franco Valle | Chief Financial Officer | A | +4,273 | +$16.16K |
| 2023-05-17 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | −25,000 | −$846.00K |
| 2023-05-10 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | −250,000 | −$8.58M |
| 2023-04-26 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | −200,000 | −$5.82M |
| 2023-04-06 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | −200,000 | −$6.25M |
| 2023-04-06 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | +200,000 | +$6.25M |
| 2023-04-03 | Cormorant Global Healthcare Master Fund, LP | 10%+ Owner | Buy | +1,600,000 | +$48.00M |
| 2023-02-10 | Rainer M Erdtmann | President and COO | Buy | +8,400 | +$142.80K |
| 2023-01-10 | Rainer M Erdtmann | President and COO | A | +118,000 deriv. | — |
| 2023-01-10 | Thomas Andrew Butler | Chief Executive Officer | A | +354,350 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Cormorant Global Healthcare Master Fund, LP | 10%+ Owner | 3,570,872 | $2.27M |
| Cormorant Private Healthcare Fund III LP | 10%+ Owner | 3,570,872 | $2.27M |
| Rainer M Erdtmann | See Remarks | 1,858,016 | $1.18M |
| Michael J.M. Hitchcock | Interim CEO | 115,000 | $73.09K |
| Franco Valle | Chief Financial Officer | 42,995 | $27.33K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BMEA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.